DBC1 functions as a tumor suppressor by regulating p53 stability

Cell Reports

Volumn 10, Issue 8, 2015, Pages 1324-1334

  Qin, Bo ^a,b   Minter Dykhouse, Katherine ^c   Yu, Jia ^c   Zhang, Jun ^b   Liu, Tongzheng ^b   Zhang, Haoxing ^b   Lee, Seung Baek ^b   Kim, Jung Jin ^b   Wang, Liewei ^c   Lou, Zhenkun ^b  

^a FUDAN UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELETED IN BREAST CANCER 1; ONCOPROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; SIRTUIN 1; UNCLASSIFIED DRUG; BRINP1 PROTEIN, MOUSE; MDM2 PROTEIN, MOUSE; NERVE PROTEIN; PROTEIN BINDING; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INCIDENCE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DBC1 GENE; DNA DAMAGE; DOWN REGULATION; GENE FUNCTION; GENE LOSS; IN VITRO STUDY; IN VIVO STUDY; LIVER TUMOR; LYMPHOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; TERATOMA; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE FREE SURVIVAL; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROTEIN STABILITY; RNA INTERFERENCE;

MUS;

ANIMALS; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84924591628     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.01.066     Document Type: Article

References (40)

1. Anantharaman V., Aravind L. Analysis of DBC1 and its homologs suggests a potential mechanism for regulation of sirtuin domain deacetylases by NAD metabolites. Cell Cycle 2008, 7:1467-1472.
2. Armit C.J., O'Dea S., Clarke A.R., Harrison D.J. Absence of p53 in Clara cells favours multinucleation and loss of cell cycle arrest. BMC Cell Biol. 2002, 3:27.
3. Bae J.S., Park S.H., Kim K.M., Kwon K.S., Kim C.Y., Lee H.K., Park B.H., Park H.S., Lee H., Moon W.S., et al. CK2alpha phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients. Int. J. Cancer 2014, 136:797-809.
4. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4:793-805.
5. Brady C.A., Attardi L.D. p53 at a glance. J.Cell Sci. 2010, 123:2527-2532.
6. Cha E.J., Noh S.J., Kwon K.S., Kim C.Y., Park B.H., Park H.S., Lee H., Chung M.J., Kang M.J., Lee D.G., et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 2009, 15:4453-4459.
7. Chen D., Shan J., Zhu W.G., Qin J., Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010, 464:624-627.
8. Coutts A.S., Adams C.J., La Thangue N.B. p53 ubiquitination by Mdm2: a never ending tail?. DNA Repair (Amst.) 2009, 8:483-490.
9. Dai C., Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010, 16:528-536.
10. De S., Kumari J., Mudgal R., Modi P., Gupta S., Futami K., Goto H., Lindor N.M., Furuichi Y., Mohanty D., Sengupta S. RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress. J.Cell Sci. 2012, 125:2509-2522.
11. Di Marcotullio L., Canettieri G., Infante P., Greco A., Gulino A. Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim. Biophys. Acta 2011, 1815:241-252.
12. Escande C., Chini C.C.S., Nin V., Dykhouse K.M., Novak C.M., Levine J., van Deursen J., Gores G.J., Chen J., Lou Z., Chini E.N. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J.Clin. Invest. 2010, 120:545-558.
13. Fu J., Jiang J., Li J., Wang S., Shi G., Feng Q., White E., Qin J., Wong J. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J.Biol. Chem. 2009, 284:6832-6840.
14. Garapaty S., Xu C.F., Trojer P., Mahajan M.A., Neubert T.A., Samuels H.H. Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J.Biol. Chem. 2009, 284:7542-7552.
15. Hamaguchi M., Meth J.L., von Klitzing C., Wei W., Esposito D., Rodgers L., Walsh T., Welcsh P., King M.C., Wigler M.H. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc. Natl. Acad. Sci. USA 2002, 99:13647-13652.
16. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
17. Hermannstädter A., Ziegler C., Kühl M., Deppert W., Tolstonog G.V. Wild-type p53 enhances efficiency of simian virus 40 large-T-antigen-induced cellular transformation. J.Virol. 2009, 83:10106-10118.
18. Heyer B.S., MacAuley A., Behrendtsen O., Werb Z. Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. Genes Dev. 2000, 14:2072-2084.
19. Hiraike H., Wada-Hiraike O., Nakagawa S., Koyama S., Miyamoto Y., Sone K., Tanikawa M., Tsuruga T., Nagasaka K., Matsumoto Y., et al. Identification of DBC1 as a transcriptional repressor for BRCA1. Br. J. Cancer 2010, 102:1061-1067.
20. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
21. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4alocus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
22. Kamijo T., Bodner S., van de Kamp E., Randle D.H., Sherr C.J. Tumor spectrum in ARF-deficient mice. Cancer Res. 1999, 59:2217-2222.
23. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
24. Kang Y., Jung W.Y., Lee H., Lee E., Kim A., Kim B.H. Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma. Korean J. Pathol. 2012, 46:523-531.
25. Kim J.E., Chen J., Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008, 451:583-586.
26. Kim J.E., Chen J., Lou Z. p30 DBC is a potential regulator of tumorigenesis. Cell Cycle 2009, 8:2932-2935.
27. Koyama S., Wada-Hiraike O., Nakagawa S., Tanikawa M., Hiraike H., Miyamoto Y., Sone K., Oda K., Fukuhara H., Nakagawa K., et al. Repression of estrogen receptor beta function by putative tumor suppressor DBC1. Biochem. Biophys. Res. Commun. 2010, 392:357-362.
28. Lavin M.F., Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006, 13:941-950.
29. Lehnertz B., Rogalski J.C., Schulze F.M., Yi L., Lin S., Kast J., Rossi F.M. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol. Cell 2011, 43:673-680.
30. Leung K.M., Po L.S., Tsang F.C., Siu W.Y., Lau A., Ho H.T., Poon R.Y. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res. 2002, 62:4890-4893.
31. Li Z., Chen L., Kabra N., Wang C., Fang J., Chen J. Inhibition of SUV39H1 methyltransferase activity by DBC1. J.Biol. Chem. 2009, 284:10361-10366.
32. Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25:304-317.
33. Nin V., Escande C., Chini C.C., Giri S., Camacho-Pereira J., Matalonga J., Lou Z., Chini E.N. Role of Deleted in Breast Cancer 1 (DBC1) Protein in SIRT1 Deacetylase Activation Induced by Protein Kinase A and AMP-activated Protein Kinase. J. Biol. Chem. 2012, 287:23489-23501.
34. Noguchi A., Kikuchi K., Zheng H., Takahashi H., Miyagi Y., Aoki I., Takano Y. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. 2014, 3:1553-1561.
35. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19:607-614.
36. Sundararajan R., Chen G., Mukherjee C., White E. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene 2005, 24:4908-4920.
37. Vousden K.H., Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137:413-431.
38. Yuan J., Luo K., Liu T., Lou Z. Regulation of SIRT1 activity by genotoxic stress. Genes Dev. 2012, 26:791-796.
39. Zhang Y., Gu Y., Sha S., Kong X., Zhu H., Xu B., Li Y., Wu K. DBC1 is over-expressed and associated with poor prognosis in colorectal cancer. Int. J. Clin. Oncol. 2014, 19:106-112.
40. Zhao W., Kruse J.P., Tang Y., Jung S.Y., Qin J., Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008, 451:587-590.